Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis by Winklhofer-Roob, B.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/21954
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
, * ! ■  K .  „ r
P e r g a m o n
Free Kadienl Biology & Medicine, Vol. 18, No. ,*5, pp. 849 - N.V), PW5
Copyright CO lc)(>5 Hlscvier Science Ltd 
Printed in the USA. All rights reserved
08<>|-584«5 $9.50 -I- ,(H)
0801 -5849(94)00203-7
Original Contribution
ß
NCE TO OXIDATION OF LOW DENSITY 
BCREASED LIPID PEROXIDE FORMATION 
SUPPLEMENTATION IN CYSTIC FIBROSIS
B u ic i i r n i  M . W inki.iio i-hr-Rooh,* H i;r iii ;r t  I>u n i „ t G i i o i .a m a i .i K h o s c h s o r u r ,*
M a r t i n  A. v a n ' t  Hoi\® H h r m a n n  C s t h r b a u k r , 1 and D a v i d  H . S h m u r l i n g *
^Oivision ol Gastroenterology and Nutrition, Department of Pediatrics, University of Zurich, Switzerland; 
institute ol Biochemistry anil 'Department of Surgery, University of Graz, Austria; and 5MedicaI Statistics Department,
University of Nijmegen, The Netherlands
{Received 12 April 1994; Revised 15 September 1994; Accepted 22 September 1994)
A b s t r a c t  We investigated the effect of correcting //-carotene deliciency in cystic iibrosis (CP) patients on two parameters of 
lipid peroxidation: The resistance to oxidation of low density lipoprotein (LDL) was measured by the lag time preceding the 
onset of conjugated diene formation during exposure to eopper(I[) ions, and lipid peroxide formation was quantitated by 
malomlialdehyde concentrations itt plasma (TBA/I1PLC method), Simultaneously, re-tocopherol and /3-carolene concentrations 
were determined in LDL and in plasma. Thirty-‘ lour CF patients were investigated before and after 3 months of oral //-caroleno 
.supplementation. /Icarotene concentrations increased (p < 0,0001) in plasma (mean SD) (0.09 0.06 vs. 1.07 :J: 0.86 
/nnol/l) and in 1.1)1, (0.02 > 0.02 vs. 0.31 1 0*28 mol/mol), without significant changes in «-tocopherol, either in plasma (24.7
1 5.9 vs, 25.4 1 7.6) or in LDL (8.47 2.95 vs. 9.05 4.13), Lag times, being shorter {p < 0.05) in patients than in controls, 
increased from 48.5 ! 21.3 to 69.1 ■ 27.9 min (p *" 0.001) and plasma MDA concentrations, being greater (p < 0 .0 0 0 1 ) in 
patients than itt controls, decreased from 0.95 * 0.32 to 0.61 ± 0,15 /¿mol/l (p < 0.0001), At 3 months, lag times and MDA 
concentrations did not any longer differ between patients and controls. These data suggest that excess lipid peroxidation occurring 
in // caiotene deficiency can he limited and normalized during efficient //-carotene supplementation in CF patients.
Keywords a -Tocopherol, f l»Carotene, Lipid peroxidation, Conjugated dicncs, LDL, Malondtaldehyde, Free radicals, Cystic 
Iibrosis
INTRODUCTION
A growing number of studios addressed the effect of 
/¡^carotene on the resistance to oxidation of low den­
sity lipoprotein (LDL) in subjects with a normal or 
marginal /i-carotene status prior to supplementation/ 
resulting in extremely high /7-carotene values up to 10 
to 20 times normal,' which hardly reflect a physiologi­
cal but rather an experimental condition. In contrast, 
only limited data* ; are available allowing us to answer 
the question of whether an almost complete lack of /?- 
earotene in human subjects substantially deteriorates 
the antioxidant protection of polyunsaturated fatty 
acids in LDL and biomembranes and thus leads to 
increased lipid peroxide formation. The same holds 
true for the effects of correcting this deficiency, main I y
Address correspondence to: HrigiUe M. Winklhofcr-Rooh, Depart­
ment of Pediatrics, University of Zurich, The Children’s Hospital, 
Steinwies.sirasse 75, CII-8032 Zurich, Switzerland.
due to the fact that severe /3-carotene deliciency is 
limited to a few pathological conditions, comprising 
an impaired intestinal absorption of this micronutri­
ent,5/1 or to healthy subjects after experimental 
depletion.
Cystic fibrosis (CP) patients frequently exhibit se­
vere /3-carotene deficiencyK,t* due to exocrine pancre­
atic insufficiency and thus represent a clinical setting 
for investigating the role of /3-carotene on lipid peroxi­
dation. In view of increased free radical generation 
from inflammatory cells in chronic lung inflammation*” 
on one hand and combined antioxidant deficiencies11 
on the other, CF patients arc at increased risk of exhib­
iting a shift in the oxidant-antioxidant balance in favor 
of the former. We hypothesized that /3-carotene defi­
ciency aggravates this imbalance, leading to excess 
lipid peroxidation, which in turn could result in en­
hanced propagation of disease processes, for example, 
in the lung and in the liver of these patients.12 N
We first addressed the question of whether LDL of
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vitamin E-sufficient but /3-carotene-deficient CF pa­
tients exhibits an impaired resistance to oxidation and 
if, after correction of /3-carotene deficiency in vivo, 
isolated LDL, the main carrier of /3-carotene in the 
blood,15 can withstand this oxidative stress more effi­
ciently than before supplementation. Second, we fo­
cused on the hypothesis that, due to the oxidant-anti- 
oxidant imbalance in favor of the former, plasma lipid 
peroxide levels are increased in CF patients with un­
corrected /2-carotene deficiency, but can be decreased 
during supplementation. Thus, this study was designed 
to answer the question of whether /3-carotene supple­
mentation of vitamin E-sufficient but /3-carotene-defi- 
cient CF patients would result in an enhanced protec­
tion against lipid peroxidation. If so, this could provide 
the basis for a new therapeutic concept for patients 
with this complex inherited metabolic disorder. In ad­
dition, the results obtained in this study are expected 
to contribute to the present knowledge16 about the bio­
logical properties of /2-carotene.
METHODS
Study design
The oxidation resistance of and the antioxidant 
concentrations in LDL were determined in /?-carotene- 
deficient CF patients at study entry (baseline values) and 
after 3 months of /3-carotene supplementation. Plasma 
concentrations of MDA, antioxidants, and cholesterol 
were quantitated at study entry, after 3 weeks and 3 
months of treatment. Controls had a single evaluation, 
including the same parameters as assessed in patients, 
to allow, by comparison, validation of baseline values 
of patients and evaluation of treatment efficacy.
Subjects
Patients. CF patients, under long-term care in the CF 
outpatients clinic of the Department of Pediatrics, 
University of Zurich, with plasma /3-carotene 
concentrations <  0.32 fimol/1 (mean -  1 SD of age- 
matched Swiss controls, Winklhofer-Roob et aL, unpub­
lished data) and enrolled in a /3-carotene supplementa­
tion trial, were eligible for inclusion in this investigation 
if they had both LDL and plasma a-tocopherol concen­
trations above mean -  2 SD of healthy subjects, that 
is, for LDL, 2.22 mol/mol, derived from mean = 7.26, 
SD = 2.52 mol/mol, established for a healthy Austrian 
population in the same laboratory where the present 
investigations were done17 and for plasma, 15.9 pmo]/
1, derived from mean = 29.3, SD = 6.7 ¿¿mol/1, 
established by Vuilleumier et al.18 in the laboratories of 
the Vitamin Research Department of Hoffmann-La
Roche Ltd., Basel, Switzerland, where the plasma anti­
oxidant measurements in this study were performed. 
Thirty-four of 37 patients enrolled in the /3-carotene 
supplementation study, 18 M, 16 F, ages 10.8 ± 7,6 
years, fulfilled the inclusion criteria. All had been on 
oral vitamin E supplements (330 ± 120IU daily, RRR- 
a-tocopherol, MULTABENR, Roche Pharma Ltd., Ba­
sel, Switzerland, or all-rac-a-tocopheryl acetate, 
EPHYNALr, Hoffmann-La Roche Ltd., Basel,
*
Switzerland) at least during one year prior to this study. 
The diagnosis of CF had been established by typical 
clinical symptoms and elevated sweat electrolytes.19 The 
patients1 Shwachman scores20 were 84 ± 12. All pa­
tients were in a stable disease status, none had an acute 
exacerbation at any of the three evaluations. All patients 
exhibited exocrine pancreatic insufficiency, which was 
treated with pancreatic enzymes (CREONr, KaliChemie 
Ltd., Bern, Switzerland, or PANZYTRAT 25000R, 
Knoll Ltd., Liestal, Switzerland), the dosages (310,000 
± 260,000 FIP units) being individually adjusted to the 
results of repeated fat balance studies prior to study 
entry. The actual coefficients of fat absorption were 83.0 
± 10.3%. Patients were on a free diet containing 30- 
40% of energy as fat as evaluated from repeated 72 h- 
food records before enrollment in this investigation. At 
study entry, 17 patients were taking 200-2000 ml (890 
± 550 kcal/day) of liquid formulas (FRESUBINr , Fre- 
senius Ltd., Stans, Switzerland, NUTRODRIPr , San- 
doz-Wander Ltd., Bern, Switzerland, or TWOCALR, 
Abbott Ltd., Cham, Switzerland) as part of the therapeu­
tic regime routinely applied in order to meet the caloric 
needs and did so throughout the study period. No other 
changes were introduced into the diet. Three patients 
who were on long-term oral retinyl palmitate supple­
ments (AROVITR, Hoffmann-La Roche Ltd.) and nine 
patients who were on a multivitamin preparation (PRO- 
TOVITR, Hoffmann-La Roche Ltd.) continued to take 
the vitamins. None had had /?-carotene supplements 
prior to study entry. Other medications, included in the 
overall therapeutic regime, for example, antibiotics, ap­
plied orally and/or by aerosol to 10/32 patients at study 
entry and to 4 additional patients after 3 months, were 
maintained without introduction of new drugs during 
the study period. Clinical characteristics of patients at 
baseline and after 3 months of supplementation, com­
prising nutritional (weight, upper arm circumference; 
albumin, prealbumin) and infectious parameters (C- 
reactive protein, a {-acid glycoprotein, bands as % of 
WBC), did not change. Two patients were lost to follow- 
up. For five other patients, either baseline (n — 4) or 3 
month values (n = 1) for the LDL resistance to oxidation 
were not available. Thus, data from 27 and 32 patients 
for determinations of the LDL resistance to oxidation 
and plasma MDA concentrations, respectively, could be 
included in statistical analysis.
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Controls. Fourty-two clinically healthy stalT members 
of the Department of Pediatrics, University of Zurich, 
15 ML 27 F, ages 31.5 ± 8.0 years, were recruited to 
participate in this study, as it was ethically not accept­
able to draw the necessary amounts of blood from 
healthy children. All persons were on a usual mixed 
diet, all but two were non-smokers, all but one (who 
took regularly 500 mg vitamin C daily) did not use 
vitamin supplements. Twelve women were on oral 
contraceptives. Twenty-two of these volunteers, 10 M, 
12 I\ ages 35.1 8.2 years, had also determinations 
of the LDL resistance to oxidation; for two of them, 
data on the LDL content of antioxidants were missing. 
From one volunteer no blood was available for the 
measurement of plasma MDA concentrations. In the 
plasma sample obtained from another volunteer, hemo­
lysis had occured. As this has been reported to influ­
ence the MDA-TBA test results/’1 this person was ex­
cluded from further evaluation. Consequently, data 
from 40 subjects for MDA concentrations were in­
cluded in statistical analysis.
vided into aliquots for quantification of antioxidants 
and determination of the LDL resistance to oxidation.
Therapeutic intervention
During the study period, patients received /?-earo- 
tene orally in a daily dosage of 0.5 mg/kg body weight, 
given during breakfast in capsules containing 5 mg 
synthetic //«carotene as 10% water-miseible beadlets, 
with 80%' all-trans and 20% cis isomers (BBLLACAR- 
OTiNl\  3M Medica, Ltd., Borken, Germany).
Ethical considerations
'l'he study was approved by the Ethical Committee 
of the Department of Pediatrics, University of Zurich, 
and informed consent was obtained from the patients 
or their parents as well as from healthy controls.
Plasma sampling and preparation of fJ)L
After an overnight fast, blood was drawn in sterile 
plastic tubes, containing K-HDTA (1.6 mg/ml) as an 
anticoagulant (Sarstedt Monovette'S Nümbrecht, Ger­
many), protected from light by aluminum foil and cen­
trifuged immediately at 2000 g for 8 min. Plasma was 
separated and samples were divided into aliquots for 
the different determinations. While kept cool on ice, 
an aliquot of KDTA supplemented plasma from each 
patient was shipped by overnight courier, and within 
36 h after blood was drawn, LDL was isolated by 
density gradient ultracentrifugation in a density range 
of 1.02 -1.05 g/ml (swingout rotor SW-41,40000 rpm, 
I0 - I5 ° t \  20 -24 h). LDL was then removed and di­
Detennination o f  the LDL resistance to oxidation
Immediately after isolation, LDL was processed for 
determination of the resistance to oxidation. Separation 
of LDL from EDTA and salts of the density gradient 
was performed by gel-filtration using Biogcl P6-DG 
(EconoPac DG columns, Biorad, Inc., Hercules, CA). 
LDL was diluted to 0.25 mg/ml LDL mass (corre­
sponding to 50 /¿g LDL protein) in oxygen saturated 
phosphate buffered saline, pH 7.4* Oxidation was initi­
ated by exposure of LDL to 16.6 fiM Cu2 i , and CD 
absorbance at 234 nm was recorded spectrophotometri- 
cally (UV 1202, Shimadzu, Inc., Japan) in 1 cm cu­
vettes with automatic cuvette changing in 2 min inter­
vals. The relative increase in CD absorbance was con­
tinuously monitored until LDL was fully oxidizcd.‘LU* 
From the 234 nm trace, the lag time (Index I of the 
oxidation resistance of LDL) was determined as the 
intercept of the tangent on the first turning point with 
the time axis. The maximum rate of oxidation (Index 
II of the oxidation resistance), corresponding to the 
slope at the turning point, was calculated (clA/min), 
and the time of occurrence was recorded. Finally, the 
maximum increase in CD absorbance (Index III) and 
the corresponding time point were determined. This 
assay has proved to be a reliable and reproducible 
method for the determination of the oxidation resis­
tance of LDL, with an intra-assay coefficient of varia­
tion of 1.9% and an inter-assay coefficient of variation
of 4.4%.m
Determination o f  antioxidants in LDL
Aliquots of isolated LDL samples containing EDTA 
were stored at —70°C until a-  and y-tocopherol and 
carotenoids (^-carotene, lycopene, lutein/zeaxanthin, 
cryptoxanthin) were determined by different HPLC 
methods: for tocopherols as described by Vuilleumicr 
et al.IM and Esterbauer et al.2il and for carotenoids by 
a modified method of Bieri et al.26 Acetomtrile: methy- 
lenchloride: methanol = 67:19:14 was used as mobile 
phase with a ilow rate of 1.3 ml/min.2/ All concentra­
tions were expressed as mol/mol total LDL.
Determination o f  antioxidants in plasma
Another portion of plasma was kept frozen at — 20°C 
for a maximum of 4 days before determination of 
plasma antioxidants (¿»tocopherol, a -  and 0-carotene, 
lycopene) by HPLC according to Hess et al.2R
852 B. M. Winklhofer-Roob et a i
Table 1. Antioxidants in LDL and Parameters of LDL Oxidation in Patients at Baseline and After
3 Months of Supplementation as Well as in Healthy Controls
Controls
Patients (n = 27) (n =  22a) p Values
Baseline A 3 Months B C A vs. Bb A vs. Cc B vs. Cc
I. Antioxidants in LDL (mol/mol) 
a-Tocopherol
/3-Carotene
II. Parameters of LDL oxidation 
Lag time (min)
Maximum rate of oxidation
d A/m in 
At time (min)
Maximum increase in CD absorbance 
A234 nm 
At time (min)
8.47 2.95 9.05 -+■ 4.13 6.40 1.26 NS <  0.05 <  0 . 0 1
0 . 0 2 0 . 0 2 0.31 0.28 0.31 0.24 <  0.0001 <  0.0001 NS
48,5 ± 21.3 69.1 ± 27.9 62.5 ±  2 2 . 8 <  0.001 <  0.05 NS
0,026 ± 0.007 0.026 0.008 0.023 0.006 NS NS NS
69.3 ± 23.9 89.6 ± 33.3 84.3 -4“ 26.7 <  0 . 0 0 1 <  0.05 NS
0.83 0.11 0.82 0.14 0.77 ± 0.08 NS NS NS
98.8 ± 26.8 119.1 ± 38.3 117.4 ± 34.2 <  0 . 0 1 NS NS
dA/min = Changes in conjugated diene absorbance/min; CD = Conjugated dienes; NS = not significant. Values are expressed as mean 
SD.
a Data on antioxidants in LDL were obtained in 20 controls. 
b Wilcoxon matched pairs signed ranks tests, two-tailed, 
c Mann -Whitney U tests, two-tailed.
Determination of lipid peroxides in plasma
Another aliquot of EDTA plasma was stored at 
—70°C until lipid peroxides were determined by HPLC 
measurement of the MDA-TBA adduct according to 
Wong et al.21 as described previously.29 Coefficients 
of variations of repeated MDA-TBA assays in our lab­
oratory were 4.4% (within run) and 6.9% (from run to 
run), respectively (unpublished data).
Determination of plasma cholesterol concentrations
Plasma cholesterol concentrations were measured 
enzymatically, using commercially available kits from 
Beckman, Ltd., Brea, CA, for the patient group and 
from Merck, Ltd., Darmstadt, Germany, for the control 
group. Ratios of plasma a-tocopherol to cholesterol 
were calculated to correct for differences in cholesterol 
concentrations between patients and controls. HDL 
cholesterol was determined with the CHOD-PAP kit 
from Boehringer Mannheim, Ltd., Mannheim, Ger­
many, and LDL and VLDL cholesterol with a kit from 
BioMerieux Suisse SA, Geneva, Switzerland.
Statistical analysis
Statistical analysis was performed at the Medical 
Statistics Department, University of Nijmegen. Due to 
nonconformity of the data with the normality assump­
tion, Wilcoxon matched pairs signed ranks tests were 
used to compare study variables in patients at baseline 
with those after 3 months of supplementation, Mann- 
Whitney U tests for the corresponding comparisons
between patients and controls, and Spearman rank cor­
relation coefficients were calculated for the associa­
tions between different variables. Log-transformation 
was performed to obtain normality for further analysis. 
Multiple regression analysis was used to analyze the 
relationship between parameters of lipid peroxidation 
(lag time and plasma MDA values) and antioxidants. 
To further estimate the efficiency of /3-carotene, cor­
rection for changes in LDL a-tocopherol was made on 
the basis of the results of regression analysis. Stat- 
graphics (STSC, Inc., Rockville, MD) Version 6 was 
used for all statistical procedures. Differences were 
considered significant at p <  0.05. All results are ex­
pressed as mean ± SD unless otherwise stated.
RESULTS
Antioxidants in LDL
a- and y-Tocopherol. At study entry, LDL a-tocoph­
erol concentrations of patients were significantly 
higher than those of controls due to long-term vitamin 
E supplementation prior to this study. For the whole 
study group, they did not change significantly between 
baseline and 3 months (Table 1, Fig. 1A). In individual 
patients, however, changes in a-tocopherol greater 
than 10% of baseline values did occur during /3-caro­
tene supplementation, comprising both increases (n =
11, 35 ±  7%) and decreases (n = 6,40 ± 28%)* Levels 
of -y-tocopherol were lower (p <  0.0001) in patients 
(0.15 ± 0 .17  mol/mol) than in controls (0.31 ± 0 .1 7  
mol/mol) at study entry and remained low throughout 
the study period.
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Fig. 1. Box and whisker plots of (A) LDL a-tocopherol concentrations, (B) LDL /3-carotene concentrations, and (C) lag times 
for patients at study entry (baseline) and after 3 months of /3-carotene supplementation as well as for controls (upper, middle, 
and lower panels of the left part of the figure), Box and whisker plots of (D) plasma a-tocopherol concentrations, (E) plasma 
/9-carotene concentrations, and (F) plasma MDA concentrations for patients at study entry (baseline), after 3 weeks and 3 months 
of treatment as well as for controls (corresponding panels of the right part). The symbol ffl indicates “ far outliers” .
/3-Carotene. Baseline LDL /3-carotene concentrations 
of patients were significantly lower (p <  0.0001) than 
those of controls (Table 1, Fig. IB), with values close 
to the detection limit in a considerable proportion of 
patients. They were also far below published mean 
values (0.29 mol/mol) of healthy subjects.14,28 After 3 
months of /3-carotene supplementation, LDL /3-caro­
tene concentrations of patients had significantly in­
creased (p <  0.0001) by 0.29 ± 0.28 mol/mol LDL 
and did not differ any longer from those of controls. 
As evidenced by the large SD, patients responded to 
supplementation with substantial between-subject vari­
ation. In a single patient, identified as far outlier in 
Figure IB, an increase in LDL /3-carotene concentra­
tion of 1.45 mol/mol was observed.
Other carotenoids. At study entry, patients showed 
significantly lower (p <  0,0001) LDL contents of lyco- 
pene (0.04 ± 0.04 mol/mol), lutein/zeaxanthin (0.002 
± 0.002 mol/mol) and cryptoxanthin 0.005 ± 0.001
mol/mol) than controls (0.37 ± 0.16, 0.012 ± 0.004, 
and 0.076 ± 0.049 mol/mol, respectively). In patients, 
lycopene and lutein/zeaxanthin concentrations did not 
change in LDL between study entry and 3 months, 
whereas cryptoxanthin levels increased about twofold 
(p <  0.0001) to 0.010 ± 0.007 mol/mol, but still re­
mained very low compared to those of healthy subjects.
0
LDL Resistance to oxidation
Parameters of LDL oxidation, as characterized by 
the CD absorbance curve, that is, lag time (Index I of 
the oxidation resistance), maximum rate of oxidation 
(Index II), and maximum increase in CD absorbance 
(Index III), are presented for the whole study group in 
Table 1.
At baseline, lag times were significantly (p <  0.05) 
shorter in patients than in healthy controls (Table 1). 
Multiple regression analysis showed that lag times 
were significantly related to LDL a-tocopherol concen-
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trations {p = 0.003), but not to values of /3-carotene, 
which was present in very small concentrations as
shown in Table 1.
After 3 months of /3-carotene supplementation with
an increase in LDL /3-carotene concentrations as de­
scribed above, lag times of patients had significantly 
increased (p <  0.001) by 20.6 ± 25.2 min, and the 
resulting lag times of 69.1 ± 27.9 min did not any 
longer differ from those of controls (Table 1, Fig. 1C). 
The increase in lag times varied substantially between 
patients, as indicated by the large SD. Multiple regres­
sion analysis was unable to identify a correlation be­
tween the increase in lag times and the increase in 
the log of LDL 0-carotene concentrations (p = 0.58). 
Changes in lag times were statistically related (p = 
0.005) to changes in LDL a-tocopherol levels, oc­
curring during /3-carotene supplementation and com­
prising both increases and decreases. The resulting re­
gression line of changes in lag times on changes in 
LDL a-tocopherol concentrations showed a slope of
(mean SE) 5.6 ± 1.8 min/mol a-tocopherol/mol
LDL, representing an index of the efficiency of a- 
tocopherol30 The change in lag time when the a-to- 
copherol level is kept constant is indicated by the inter­
cept of (mean ± SD) 17.4 ± 4.3 min (Fig. 2). Thus, 
changes in a-tocopherol concentrations explained only
3.2 min out of the total increase in lag times of 20.6 
min observed during the study period. Changes in lag 
times after correction for changes in a-tocopherol, that 
is, a mean increase of 17.4 min, were still significantly 
positive {p < 0.001). Because no other variables were 
changed, these changes are attributable to the changes 
in LDL 0-carotene, the therapeutic intervention during 
the study period. Patients exhibiting an increase in 
LDL a-tocopherol greater than 10% of baseline values, 
in addition to the increase in LDL 0-carotene (Fig. 2, 
Group C, n -  11), showed greater increases in lag 
times than did those with changes within 10% (Group 
B, n = 10) or with a decrease exceeding 10% of base­
line values (Group A, n = 6). In Figure 3A, line plots 
of changes in lag times (corrected for changes in LDL 
a-tocopherol) against changes in LDL 0-carotene con­
centrations are presented for the individual study pa­
tients. In 22 of 27 patients lag times increased during 
0-carotene supplementation. However, there was a 
great variability in the slopes, indicating a substantial 
between-subject variability in the efficiency of 0-caro- 
tene on the increase in lag times. As a consequence, 
changes in LDL 0-carotene concentrations per se were 
not able to predict the changes in lag times in the 
patient population investigated in this study. In view 
of the great between-subject variability, large scale 
clinical trials are needed to establish the relationship 
between these variables.
Change in LDL a-tocopherol (mol/mol)
Fig, 2. Regression of changes in lag time on changes in LDL a- 
tocopherol concentrations during /?-carotene supplementation. The 
regression line shows a significant (p = 0.005) slope of 5.6 (SE, 
1.8) min/mol a-tocopherol/mol LDL. The intercept of 17.4 min (SE, 
4,3) indicates the changes in lag time at a constant LDL a-tocopherol 
level. Patients with changes in LDL a-tocopherol within 10% of 
baseline (group B, /? = 10) are displayed in the shaded area, patients 
with a decrease (group A, n ~ 6) or with an increase greater than 
10% (group C, n = 11) are shown on the left and right panels, 
respectively. The mean ± SE values for changes in lag time are 
indicated for each group.
Neither the maximum rate of oxidation (Index II) 
nor the maximum increase in CD absorbance (Index 
III) did change during 0-carotene supplementation 
(Table 1). As a result of a significant increase in lag 
times, the maximum rate of oxidation occurred later 
at 3 months than at study entry {p <  0.001), as did
the maximum increase in CD absorbance (p <  0.01). 
No differences in these indices of the LDL resistance 
to oxidation were found between patients and con­
trols either at study entry or after 3 months of 
supplementation.
Antioxidants in plasma
a-Tocopherol Baseline plasma a-tocopherol concen­
trations were significantly lower in patients than in 
healthy controls (Table 2, Fig. ID), in contrast to 
higher LDL a-tocopherol values and higher ratios of 
plasma a-tocopherol to cholesterol due to significantly 
lower cholesterol concentrations of the study patients 
(Table 2). Plasma a-tocopherol levels of control sub­
jects (28.3 ± 6.2 /¿mol/1) were comparable to those 
previously reported by Vuilleumier et al. for healthy 
Swiss adults (29.3 ± 6.7 jLimol/l).18 During 3 months 
of 0-carotene supplementation plasma a-tocopherol 
concentrations did not change in the whole study group 
(Table 2). Changes greater than 10% of baseline values
/?-carotene and lipid peroxidation in CF 855
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patients, and MDA concentrations decreased in all but three. For 
display reasons, values obtained after 3 weeks of supplementation 
for plasma /3-carotene and MDA concentrations are not included in 
the Figure.
occurred in nine patients exhibiting an increase of 35 
± 1 3 % and in seven patients exhibiting a decrease of 
28 ± 12%.
fi-Carotene. At study entry, patients showed signifi­
cantly lower plasma /3-carotene concentrations than 
study controls (Table 2, Fig. IE). Plasma /3-carotene 
levels increased rapidly up to 3 weeks, and a further
small but still significant increase (p <  0.05) was ob­
served between 3 weeks and 3 months. Values 
achieved both at 3 weeks and 3 months did no longer 
differ from those of controls. The patient with an ex­
ceptionally high increase in LDL 0-carotene exhibited 
a corresponding increase in plasma 0-carotene (Fig. 
IB and E). The all-trans isomer accounted almost ex­
clusively for the increase in total plasma 0-carotene
concentrations, and only small changes in cis isomers 
did occur. Control subjects not taking supplements 
showed a similar distribution of the two isomers.
Other carotenoids. Plasma a-carotene concentrations 
were significantly lower (p <  0.001) in patients than 
in controls (0.01 ± 0.01 ¿¿mol/1 vs. 0.27 ± 0.19 
pmol/Y). They increased twofold between study entry 
and 3 weeks and threefold between study entry and 
3 months, yet the amounts detected in the patients’ 
samples still remained extremely low (0.02 ± 0.02 
/¿mol/1 and 0,03 ± 0.02 ¿zmol/1, respectively). 
Plasma lycopene levels were significantly lower in 
patients than in healthy subjects at study entry (0.07 
± 0.08 /¿mol/1 vs. 0.59 ± 0.21 /¿mol/1) and through­
out the observation period (3 weeks, 0.06 ± 0.07 
pmol/l, 3 months, 0.06 ± 0.07 pmol/l).
Plasma MDA concentrations
Baseline plasma MDA concentrations of patients 
were significantly greater than those of controls (Table 
2, Fig. IF), with a maximum of 1.94 pmol/l. Multiple 
regression analysis showed that the log of MDA con­
centrations was related neither to the log of plasma 0- 
carotene concentrations ip = 0.84) nor to the log of 
plasma a-tocopherol values (p = 0.24).
During 0-carotene supplementation, plasma MDA 
concentrations decreased successively. MDA values at 
3 weeks were already smaller than baseline values and 
there was a further decrease (p < 0.01) between 3 
weeks and 3 months. A substantial between-subject 
variation was observed, but overall there was a 36% 
reduction of MDA values. At 3 months, MDA concen­
trations of patients did not any longer differ from those 
of controls (0.61 ± 0.22 ¿¿mol/l) (Table 2). The latter 
were in good agreement with those published for 
healthy subjects by Wong et al. (0.60 ± 0.13 ¿¿mol/1).21 
Multiple regression analysis showed that, like the situ­
ation at study entry, also changes in the log of plasma 
MDA concentrations were neither related to changes 
in the log of plasma 0-carotene values (p = 0.97) nor 
to those in the log of plasma a-tocopherol levels (p -  
0.14). As shown in Figure 3B, in all but three patients 
the increase in plasma 0-carotene concentrations was 
accompanied by a decrease in plasma MDA values, 
but the efficiency of 0-carotene on plasma MDA con­
centrations was highly subject-specific. The mean 
(±SE) value of the slopes calculated for the regression 
of plasma MDA values on plasma 0-carotene values 
(measured at baseline, after 3 weeks and 3 months) 
for the individual patients was —0.40 (± 0.07) /zmol/
1 MDA//imol/l 0-carotene, indicating the average effi-
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Table 2. Plasma Concentrations of Antioxidants and MDA in Patients at Baseline and After
3 Months of Supplementation was Well as in Healthy Controls
Patients (n = 32)
Controls 
in = 40) p  Values
Baseline A 3 Weeks B 3 Months C D A vs. e A vs. Dh C vs. Db
I. Plasma antioxidants (¿/mol/1)
o’-Tocopherol 24.7 ± 5.9 24.6 ± 6.6 25.4 ± 7.6 28.3 ±  6.2 NS <  0.05 NS
/3-Carotene 0.09 ± 0.06 0.92 ± 0.65 1.07 ±  0.86 0.99 ±  0.41 <  0,0001 <  0.0001 NS9
Cis isomers <  DL 0.04 ±  0.03 0.05 + 0,05 0.05 ± 0.03
All-trans isomers 0.09 ± 0.06 0.88 ±  0.62 1.01 ±  0.82 0.96 ±  0.39
II. Plasma MDA (¿¿mol/l)
MDA 0.95 ± 0.32 0.72 ± 0.22 0.61 ±  0.15 0.61 ± 0.22 <  0.0001 <  0.0001 NS
III. Plasma cholesterol (mmol/1)
Total cholesterol 3.39 ± 0.69 3,25 ± 0.78 3.26 ±  0.85 4.98 ±  0.97 NS <  0.0001 <  0.0001
LDL cholesterol 1.70 ± 0.43 1.70 ± 0.52 1.72 ±  0.60 ND
HDL cholesterol 1.20 ± 0.33 1.22 ± 0.40 1.18 ±  0.37 ND
a-Tocopherol: cholesterol 7.39 ± 1.73 7.68 ± 1.53 8.01 ±  2.20 5.70 ±  0.62 NS <  0.0001 <  0.0001
Values are expressed as mean ± SD; MDA ~ Malondialdehyde. 
n Wilcoxon matched pairs signed ranks tests, two-tailed. 
b Mann-Whitney U tests, two-tailed.
ciency of one mol 0-carotene on plasma MDA concen­
trations in this study.
Relations of antioxidants and parameters of lipid 
peroxidation between LDL and plasma
Both at baseline (A) and after 3 months of 0-caro- 
tene supplementation (B), a-tocopherol (1), 0-carotene
(2), and lycopene (3) levels in LDL were strongly cor­
related with plasma values (Spearman rank correlation, 
A: (1) r = 0.79, p <  0.001; (2) r = 0.76, p <  0.001;
(3) r = 0.84, p <  0.001 and B: (1) r = 0.64, p = 
0.004; (2) r = 0.81, p <  0.001; (3) r = 0.52,p  = 0.02, 
respectively). Changes in LDL 0-carotene concentra­
tions during supplementation were positively corre­
lated with changes in plasma 0-carotene levels (r = 
0.82, p <  0.0001). In contrast, there was no correlation 
between changes in a:-tocopherol concentrations in 
LDL and in plasma (r -  -0.01, p = 0.97), the changes 
in plasma being smaller than those in LDL (plasma, 
-49%  to +51% vs, LDL, -84% to +350%). Changes 
in LDL a-tocopherol concentrations were not signifi­
cantly related to changes in LDL and HDL cholesterol 
fractions (r = -0.34, p = 0.09). There was also no 
correlation between the increase in lag times and the 
decrease in MDA concentrations (r = -0.07 ,p  = 0.71) 
(r = Spearman rank correlation coefficients).
DISCUSSION
This study investigates two different parameters of 
lipid peroxidation in two different compartments (LDL 
and plasma) before and after correction of severe long­
standing 0-carotene deficiency in vitamin E-sufficient 
CF patients. To our knowledge, the data presented are 
the first addressing changes in LDL resistance to oxida­
tion in subjects severely depleted of 0-carotene with 
a subsequent repletion to LDL 0-carotene values of 
healthy individuals.
Inclusion criteria allowed only participation of 
patients with a normalized vitamin E status after 
long-term vitamin E supplementation. In the pres­
ence of low plasma cholesterol values, a frequent 
finding in these patients,31 ratios of plasma a- 
tocopherol to cholesterol and LDL a-tocopherol 
values were even about 1.3 times higher in patients 
than in healthy subjects. Patients continued to take 
vitamin E supplements during the study period, and 
a small but statistically not significant increase in 
LDL a-tocopherol values did occur. At study entry, 
lag times were significantly correlated with LDL 
a-tocopherol values, as expected from the well- 
documented antioxidant action of a-tocopherol in 
LDL.1' 4,27,32 Changes in LDL a-tocopherol levels 
in individual patients occurring during 3 months of 
0-carotene supplementation and comprising both 
increases and decreases, were also significantly 
correlated with changes in lag times. However, 
these changes explained only 3.2 min of 20.6 min 
overall increase in lag times achieved during the 
study period. Changes in LDL a-tocopherol could 
be due to changes in compliance, an increase could 
also result from a protective action of 0-carotene 
on a-tocopherol, delaying the radical-initiated con­
sumption of a-tocopherol.33
The data presented provide evidence for an additive
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protective effect of a-tocopherol and /3-carotene as 
indicated by the greatest increase in lag times in pa­
tients with an increase in both antioxidants. In in vitro- 
systems, Palozza and Krinsky demonstrated that lipid 
peroxidation can be delayed not only by a-tocopherol 
but also by /3-carotene with an additive33 or even syner­
gistic34 action of these antioxidants and discussed the 
concept that a-tocopherol could eventually prevent 0- 
carotene from exerting a pro-oxidant effect, for exam­
ple, through limiting the production of the /3-carotene 
peroxyl radical, which is hypothesized to be generated 
during the antioxidant action of /3-carotene. If this in­
deed plays an important role, the excellent vitamin E 
status of the study patients could have been contribu- 
tive or even essential for the antioxidant activity of 0- 
carotene observed in this study.
In vitro studies addressing the effects on lipid 
peroxidation of 0-carotene alone or in combination 
with a-tocopherol yielded conflicting results. 
Whereas two studies failed to show a protective role 
of 0-carotene against LDL oxidation,35,36 Jialal et 
al.37 reported an efficient inhibition of LDL oxida­
tion by 0-carotene after loading of LDL with sig­
nificant amounts of 0-carotene. The molar concen­
trations of 0-carotene used were higher than those 
found in healthy subjects17,30 and both in patients 
and in controls of this study. Whereas the LDL sam­
ples of our study patients contained on average 8 a - 
tocopherol molecules per particle, 0-carotene was 
present only in small amounts, 0.02 molecules per 
particle before and 0.31 molecules per particle after 
supplementation. This indicates that, as found for 
healthy individuals,17,30 only about one third of LDL 
particles contained a 0-carotene molecule, whereas 
others did not. However, also under this condition, 
0-carotene supplementation increased the LDL re­
sistance to oxidation in 81% of patients.
In healthy subjects taking an antioxidant prepara­
tion containing a-tocopherol, 0-carotene, vitamin C, 
and zinc2 changes in lag times ranged from about 
-20%  to +85% of baseline values. Reaven et al.3 
applied 0-carotene alone or in combination with 
either a-tocopherol or a-tocopherol plus vitamin C 
to healthy subjects during subsequent periods, leading 
to plasma concentrations up to about 5 times normal 
values for a-tocopherol and about 20 times normal 
values for 0-carotene. No effects on different 
parameters of lipid peroxidation were observed when 
0-carotene was given alone. In view of the extremely 
high increase in LDL 0-carotene values, the question 
arises if at this concentration the same effects can 
be expected as within physiological ranges. Jialal et 
a l4 evaluated a combined antioxidant preparation of 
a-tocopherol, 0-carotene, and ascorbate vs. a -
tocopherol alone in healthy volunteers and found no 
significant differences in the effects on LDL oxidation 
kinetics. In another study,1 vitamin E sufficient smok­
ers with a marginal 0-carotene status supplemented 
with 0-carotene, exhibited a 16.6-fold increase in 
LDL 0-carotene concentrations and a significant pro­
longation of lag times, but differences in lag times 
after supplementation between treatment and placebo 
group as well as those in changes of lag times between 
the two groups were not significant. Increases in lag 
times were 41% after vitamin E, but only 6% after 
0-carotene supplementation. Whereas this study on 
subjects with marginal pretreatment values showed 
only a small effect of 0-carotene on LDL resistance 
to oxidation, vitamin E-sufficient but severely 0- 
carotene-deficient CF patients enrolled in our study 
exhibited a 38% increase in lag times during correc­
tion of 0-carotene deficiency and reached values of 
healthy controls. The fact that these patients exhibited 
severe 0-carotene deficiency at study entry, whereas 
participants of other studies had normal or marginal 
values before supplementation, may explain the more 
pronounced effect of 0-carotene supplementation on 
the LDL resistance to oxidation.
The response to oral 0-carotene supplementation 
of 0-carotene concentrations in plasma and LDL of 
patients was characterized by a substantial between- 
subject variation, as was the case for the effect of 0- 
carotene on both lag times and plasma MDA 
concentrations, resulting in a lack of statistical rela­
tion between 0-carotene increase and changes in lag 
times and plasma MDA concentrations. A similar ob­
servation has already been made in healthy subjects 
supplemented with a-tocopherol,30 leading to the con­
clusion that its efficiency is subject-specific and can 
be characterized by the slope of the regression line 
of lag time on LDL a-tocopherol concentrations mea­
sured at different time points during supplementation. 
In this study, this observation is extended for 0-caro- 
tene by the highly individual but overall significant 
response in lag times and plasma MDA values to 
correction of 0-carotene deficiency. The reasons why 
the efficiency of 0-carotene shows this high subject- 
specificity are not yet clear, but several factors might 
be involved. Not only could the fatty acid content of 
LDL significantly determine the length of lag times 
and other parameters of LDL oxidation,23,38“41 as 
could other plasma and tissue lipids affect the forma­
tion of MDA, but also the efficiency of antioxidants 
added during supplementation could highly depend 
on the amount of unsaturated lipids to be protected. 
If this holds true for healthy individuals, it is supposed 
to be even more the case in a patient population with 
documented variability in the fatty acid status.42 In
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addition, other antioxidants such as ubiquinol43 and 
structural characteristics of the LDL particle44 have 
been demonstrated to determine the LDL susceptibil­
ity to oxidation. During the last years much less infor­
mation has been obtained on factors contributing to 
MDA formation. However, the oxidative stress status 
of an individual could not only determine the extent 
of lipid peroxidation taking place in tissues and or­
gans but also the efficiency of antioxidant supple­
ments, particularly in patients exhibiting increased 
formation of reactive oxygen species due to specific 
disease processes.
The study patients were clinically stable, and no 
modifications other than 0-carotene supplementation 
were introduced during the study period. Particularly, 
neither any interventions in the diet nor in the treatment 
of fat malabsorption were made which could have led 
to changes in the fatty acid status and a subsequent 
effect on the LDL resistance to oxidation.23,38“41 Pub­
lished data on healthy subjects27 document that the 
LDL resistance to oxidation determined by the assay 
used in this study is fairly constant over several weeks 
in healthy subjects,27 as do our own unpublished data 
for CF patients if the antioxidant status does not 
change. Therefore, the changes observed in this study 
can reliably be attributed to changes in the 0-carotene 
status.
No changes in the maximum rate of oxidation were 
observed during 0-carotene supplementation in our 
study, and patients had similar rates of oxidation com­
pared with controls. This finding is in agreement with 
that of Abbey et al.2 for supplementation with a com­
bined antioxidant preparation and with that of Princen 
et al.1 for 0-carotene supplementation, but contrasts to 
the observation of a significant decline in the rate of 
oxidation during a-tocopherol supplementation.1 The 
prolongation of lag times by 0-carotene without reduc­
tion of the rate of oxidation and of maximum diene 
formation could be explained by the concept of an 
inhibitory action of 0-carotene on the initiation of lipid 
peroxidation, during which the antioxidant is con­
sumed and would thus not exert any further effect on 
the propagation of lipid peroxidation.
In addition, this study documents a 1.5-fold higher 
MDA formation in CF patients with a normalized vita­
min E status, but uncorrected 0-carotene deficiency 
compared with healthy controls, which is in line with 
preliminary data from another group.5,6 In the presence 
of a normalization of plasma 0-carotene concentra­
tions, plasma MDA concentrations decreased to values 
comparable to those of controls. Also in healthy volun­
teers, depleted from 0-carotene during 2 week dietary 
restriction, a 4 month 0-carotene repletion with either 
15 or 120 mg daily was associated with a significant
decline in MDA concentrations.7 Although the group 
on the higher dosage achieved about 2.6-fold higher 
0-carotene concentrations than the other group after 
having had similar values before supplementation, no 
differences in the effects on lipid peroxides were ob­
served. These findings confirm the absence of correla­
tion between changes in plasma 0-carotene levels and 
plasma MDA concentrations observed in this study, 
suggesting that either the dosage required for a compa­
rable effect may differ substantially between individu­
als, as could be concluded from the data of this study, 
or that above a certain threshold level a further protec­
tive effect will not be observed. Obviously, much work 
remains to be done to answer these open questions 
in order to determine the most efficient antioxidant 
supplementation for different individuals.
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ABBREVIATIONS
A— absorbance
CD— conjugated dienes
CF—cystic fibrosis
MDA—malondi aldehyde
PUFAs—polyunsaturated fatty acids
TBA— thiobarbituric acid
